Skip to main content

Pemphigus Vulgaris

4
Pipeline Programs
7
Companies
9
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Monoclonal Antibody
150%
+ 8 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
2 programs
1
1
OfatumumabPhase 3Monoclonal Antibody1 trial
VAY736Phase 21 trial
Active Trials
NCT01930175Terminated13Est. Sep 2019
NCT01920477Terminated35Est. Jan 2018
Incyte
IncyteDE - Wilmington
1 program
1
ParsaclisibPhase 2Small Molecule1 trial
Active Trials
NCT03780166Withdrawn0Est. Nov 2020
Biocorp
BiocorpFrance - Issoire
1 program
1
DSG3-CAARTPhase 1/21 trial
Active Trials
NCT04422912Recruiting40Est. Jan 2029
argenx
argenxBelgium - Zwijnaarde
3 programs
ARGX-113PHASE_21 trial
efgartigimod PH20 SCPHASE_31 trial
efgartigimod PH20 SCPHASE_31 trial
Active Trials
NCT03334058Completed34Est. Oct 2020
NCT04598451Completed222Est. Aug 2023
NCT04598477Terminated183Est. Mar 2024
Cabaletta Bio
Cabaletta BioPHILADELPHIA, PA
1 program
DSG3-CAARTPHASE_1_2
Sanofi
SanofiPARIS, France
1 program
PRN1008PHASE_21 trial
Active Trials
NCT02704429Completed42Est. Jan 2020
Genentech
GenentechCA - Oceanside
1 program
Mycophenolate Mofetil PlaceboPHASE_31 trial
Active Trials
NCT02383589Completed135Est. Oct 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
argenxefgartigimod PH20 SC
argenxefgartigimod PH20 SC
GenentechMycophenolate Mofetil Placebo
SandozOfatumumab
IncyteParsaclisib
argenxARGX-113
SanofiPRN1008
SandozVAY736
BiocorpDSG3-CAART

Clinical Trials (9)

Total enrollment: 704 patients across 9 trials

NCT04598477argenxefgartigimod PH20 SC

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

Start: Jul 2021Est. completion: Mar 2024183 patients
Phase 3Terminated
NCT04598451argenxefgartigimod PH20 SC

A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

Start: Dec 2020Est. completion: Aug 2023222 patients
Phase 3Completed
NCT02383589GenentechMycophenolate Mofetil Placebo

A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)

Start: May 2015Est. completion: Oct 2019135 patients
Phase 3Completed

Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris

Start: Aug 2013Est. completion: Jan 201835 patients
Phase 3Terminated

A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris

Start: Mar 2019Est. completion: Nov 20200
Phase 2Withdrawn

A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus

Start: Oct 2017Est. completion: Oct 202034 patients
Phase 2Completed

A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris

Start: Jan 2016Est. completion: Jan 202042 patients
Phase 2Completed

Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris

Start: Dec 2013Est. completion: Sep 201913 patients
Phase 2Terminated

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Start: Sep 2020Est. completion: Jan 202940 patients
Phase 1/2Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 704 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.